Literature DB >> 3558165

The prophylactic use of ticarcillin/clavulanate in the neonate.

S B Fayed, A M Sutton, T L Turner, T A McAllister.   

Abstract

A combination of ticarcillin and clavulanic acid (ratio 15:1) was given prophylactically to 24 newborn infants at risk of infection. Serum and urine concentrations of ticarcillin and clavulanic acid were measured after the first parenteral dose. Fifteen of 22 organisms isolated from the infants were sensitive to the drug. The pharmacokinetic profile was satisfactory and the combination was well tolerated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3558165     DOI: 10.1093/jac/19.1.113

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Clinical pharmacokinetics of penicillins in the neonate: a review of the literature.

Authors:  G M Pacifici; J Labatia; H Mulla; I Choonara
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

Review 2.  New drugs. Anti-infectives.

Authors:  R Finch
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-23

3.  Ticarcillin-clavulanic acid pharmacokinetics in preterm neonates with presumed sepsis.

Authors:  A H Burstein; L E Wyble; P Gal; P R Diaz; J L Ransom; R Q Carlos; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 5.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12

6.  Pharmacokinetics of Clavulanic Acid in the Pediatric Population: A Systematic Literature Review.

Authors:  Fleur M Keij; Gerdien A Tramper-Stranders; Birgit C P Koch; Irwin K M Reiss; Anouk E Muller; René F Kornelisse; Karel Allegaert
Journal:  Clin Pharmacokinet       Date:  2022-03-31       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.